Antiemetic agents.
Wilkes
Gail
G
D000284:Administration, Oral; D000855:Anorexia / Q000139:chemically induced; D000932:Antiemetics / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000077608:Aprepitant; D001247:Asthenia / Q000139:chemically induced; D003248:Constipation / Q000139:chemically induced; D003967:Diarrhea / Q000139:chemically induced; D004347:Drug Interactions; D004415:Dyspepsia / Q000139:chemically induced; D005221:Fatigue / Q000139:chemically induced; D005334:Fever / Q000139:chemically induced; D017829:Granisetron / Q000008:administration & dosage / Q000009:adverse effects; D006261:Headache / Q000139:chemically induced; D006606:Hiccup / Q000139:chemically induced; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects; D007275:Injections, Intravenous; D007546:Isoquinolines / Q000008:administration & dosage / Q000009:adverse effects; D009025:Morpholines / Q000008:administration & dosage / Q000009:adverse effects; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D009369:Neoplasms / Q000188:drug therapy; D017294:Ondansetron / Q000008:administration & dosage / Q000009:adverse effects; D000077924:Palonosetron; D011807:Quinolizines / Q000008:administration & dosage / Q000009:adverse effects; D011812:Quinuclidines / Q000008:administration & dosage / Q000009:adverse effects; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
D000932:Antiemetics; D000970:Antineoplastic Agents; D000077608:Aprepitant; D017829:Granisetron; D007211:Indoles; D007546:Isoquinolines; D009025:Morpholines; D017294:Ondansetron; D000077924:Palonosetron; D011807:Quinolizines; D011812:Quinuclidines; C060344:dolasetron